| | |
Systemic treatments
|
Systemic CS
|
Topical treatments
|
|---|
|
MTX
|
MMF
|
TCZ
|
ADA
|
AZA
|
ETN
|
ANK
|
CiC
|
IV
|
PO
|
CS
|
Vit D
|
Tac
|
|---|
|
Current treatment
|
No of patients
|
63
|
30
|
8
|
3
|
1
|
0
|
1
|
0
|
8
|
3
|
4
|
3
|
4
|
|
Median duration treatment months (IQR)
|
16.0 (9.3–24)
|
13.0 (6.0–25.5)
|
17.5 (15.8–24.0)
|
26.3
|
14
|
n/a
|
31
|
n/a
|
7.0 (3.5–10)
|
9.3
| | | |
|
Previous treatment
|
No of patients
|
79
|
17
|
0
|
0
|
0
|
4
|
0
|
2
|
106
|
49
|
48
|
14
|
22
|
|
Remissiona
|
34
|
5
|
n/a
|
n/a
|
n/a
|
0
|
n/a
|
0
|
103a
|
45a
| | | |
|
Inefficacy
|
8
|
6
|
n/a
|
n/a
|
n/a
|
3
|
n/a
|
2
|
0
|
3
| | | |
|
Intolerance
|
37
|
6
|
n/a
|
n/a
|
n/a
|
1
|
n/a
|
0
|
3
|
1
| | | |
|
Never given
|
No of patients
|
7
|
102
|
141
|
146
|
148
|
145
|
148
|
147
|
35
|
97
|
97
|
132
|
123
|
- MTX Methotrexate, MMF Mycophenolate mofetil, TCZ Tocilizumab, ADA Adalimumab, AZA Azathioprine, ETN Etanercept, ANK Anakinra, CiC Ciclosporin, IV Intravenous, PO Oral, CS Corticosteroid, Vit D Vitamin D analogue, Tac Tacrolimus, IQR Interquartile range
- aPatients treated with steroids were often given a standard treatment course whilst being established on a DMARD/biologic which is stopped after a standard interval according to local protocol rather than remission
- The indication for commencement of a biological was not captured in this audit. A biological may have been commenced for refractory skin involvement or extra-cutaneous manifestations such as uveitis, CNS involvement or synovitis
